Christopher Arthur

3.3k total citations · 2 hit papers
46 papers, 2.0k citations indexed

About

Christopher Arthur is a scholar working on Hematology, Genetics and Oncology. According to data from OpenAlex, Christopher Arthur has authored 46 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Hematology, 22 papers in Genetics and 9 papers in Oncology. Recurrent topics in Christopher Arthur's work include Chronic Myeloid Leukemia Treatments (23 papers), Chronic Lymphocytic Leukemia Research (21 papers) and Acute Myeloid Leukemia Research (10 papers). Christopher Arthur is often cited by papers focused on Chronic Myeloid Leukemia Treatments (23 papers), Chronic Lymphocytic Leukemia Research (21 papers) and Acute Myeloid Leukemia Research (10 papers). Christopher Arthur collaborates with scholars based in Australia, United States and France. Christopher Arthur's co-authors include Timothy P. Hughes, Anthony P. Schwarer, Susan Branford, Andrew Grigg, John F. Seymour, Robin Filshie, Anthony K. Mills, David M. Ross, Xavier Thomas and Hagop M. Kantarjian and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Christopher Arthur

44 papers receiving 1.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia

2012 818 citations Hagop M. Kantarjian, Xavier Thomas et al. Journal of Clinical Oncology profile →
Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study

2013 508 citations David M. Ross, Susan Branford et al. Blood profile →

Peers

Countries citing papers authored by Christopher Arthur

Since Specialization

Citations

This map shows the geographic impact of Christopher Arthur's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christopher Arthur with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christopher Arthur more than expected).

Fields of papers citing papers by Christopher Arthur

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christopher Arthur. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christopher Arthur. The network helps show where Christopher Arthur may publish in the future.

Co-authorship network of co-authors of Christopher Arthur

This figure shows the co-authorship network connecting the top 25 collaborators of Christopher Arthur. A scholar is included among the top collaborators of Christopher Arthur based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christopher Arthur. Christopher Arthur is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Ponatinib (PON) in patients (pts) with chronic-phase chronic myeloid leukemia (CP-CML) and the T315I mutation (mut): 4-year results from OPTIC. 2024 ·Journal of Clinical Oncology ·Michael W. Deininger, Jane Apperley, Christopher Arthur, Charles Chuah, Andreas Hochhaus, Hugues de Lavallade, Jeffrey H. Lipton, Elza Lomaia, James McCloskey, Lori J. Maness, Michael J. Mauro, Beatriz Moiraghi, Carolina Pavlovsky, Gianantonio Rosti, Philippe Rousselot, (unknown), Xiaowei Ren, Alexander Vorog, Hagop M. Kantarjian, Jörge E. Cortes	0
2	Characteristics and in‐hospital outcomes of patients requiring aeromedical retrieval for pregnancy, compared to non‐retrieved metropolitan cohorts 2021 ·Australian and New Zealand Journal of Obstetrics and Gynaecology ·F Gardiner, Alice Richardson, C Roxburgh, Marianne Gillam, Leonid Churilov, (unknown), (unknown), Christopher Arthur, Cynthia Wong, Adam Morton, Leonie Callaway, Karin Lust, (unknown), Katie Foxcroft, (unknown), Lucy Zhang, (unknown), Mathew Coleman, Michael Peek	5
3	Second primary malignancies in chronic lymphocytic leukaemia: Skin, solid organ, haematological and Richter's syndrome 2021 ·SHILAP Revista de lepidopterología ·Yandong Shen, Luke Coyle, Ian Kerridge, William Stevenson, Christopher Arthur, (unknown), Keith Fay, Christopher Wård, Matthew Greenwood, Giles Best, (unknown), Alexander Guminski, Stephen Shumack, Stephen P. Mulligan	14
4	Polatuzumab Vedotin Plus Venetoclax with Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Primary Efficacy Analysis of a Phase Ib/II Study 2020 ·Blood ·Giuseppe Gritti, Paula Marlton, Tycel Phillips, Christopher Arthur, Rajat Bannerji, Paolo Corradini, Anna Johnston, John F. Seymour, (unknown), Jamie Hirata, Lisa Musick, (unknown), (unknown), Christopher R. Flowers	16
5	Intensive chemotherapy and up-front stem cell transplant for double hit lymphoma 2020 ·Bone Marrow Transplantation ·Jad Othman, (unknown), (unknown), Christopher Arthur, Keith Fay, William Stevenson, (unknown), Christopher Wård, (unknown), Luke Coyle, Ian Kerridge, Matthew Greenwood	3
6	Oral fludarabine is an effective and convenient alternative to intravenous fludarabine in fludarabine melphalan based reduced intensity conditioning regimens 2019 ·Bone Marrow Transplantation ·(unknown), Julian Lindsay, (unknown), Albert Kai-Sun Wong, Ian Kerridge, Christopher Arthur, Keith Fay, William Stevenson, Matthew Greenwood	1
7	Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cells 2018 ·Leukemia ·(unknown), David M. Ross, Ilaria S. Pagani, Naranie Shanmuganathan, Chung Hoow Kok, John F. Seymour, Anthony K. Mills, Robin Filshie, Christopher Arthur, Phuong Dang, Verity A Saunders, Jodi Braley, Agnes S. M. Yong, David T Yeung, Deborah L. White, Andrew Grigg, Anthony P. Schwarer, Susan Branford, Timothy P. Hughes	56
8	Post hoc analysis of the relationship between baseline white blood cell count and survival outcome in a randomized Phase III trial of decitabine in older patients with newly diagnosed acute myeloid leukemia 2015 ·Journal of Blood Medicine ·Christopher Arthur, Jaroslav Čermák, Jacques Delaunay, Grzegorz Mazur, Xavier Thomas, Agnieszka Wierzbowska, Mark M. Jones, (unknown), Hagop M. Kantarjian, Jiří Mayer	3
9	An imatinib-only window followed by imatinib and chemotherapy for Philadelphia chromosome-positive acute leukemia: long-term results of the CMLALL1 trial 2014 ·Leukemia & lymphoma ·Jason D. Lickliter, Kerry Taylor, Jeff Szer, Andrew Grigg, Christopher Arthur, Timothy P. Hughes, Simon Durrant, Robin Filshie, (unknown), Michael Seldon, (unknown), Andy Boyd, James D’Rozario, Kim Rooney, Kevin Lynch, Ken Bradstock, (unknown)	0
10	A Post Hoc Sensitivity Analysis of Survival Probabilities in a Multinational Phase III Trial of Decitabine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia 2013 ·Clinical Lymphoma Myeloma & Leukemia ·Xavier Thomas, Christopher Arthur, Jacques Delaunay, Mark M. Jones, (unknown), Hagop M. Kantarjian	17
11	Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia breakdown → 2012 ·Journal of Clinical Oncology ·Hagop M. Kantarjian, Xavier Thomas, Anna Dmoszyńska, Agnieszka Wierzbowska, Grzegorz Mazur, Jiří Mayer, Jyh-Pyng Gau, Wen‐Chien Chou, Rena Buckstein, Jaroslav Čermák, Ching-Yuan Kuo, Albert Oriol, Farhad Ravandi, Stefan Faderl, Jacques Delaunay, Daniel Lysák, Mark D. Minden, Christopher Arthur	818
12	Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR 2010 ·Leukemia ·David M. Ross, Susan Branford, John F. Seymour, Anthony P. Schwarer, Christopher Arthur, (unknown), Cassandra Slader, Catherine J. Field, P Dang, Robin Filshie, Anthony K. Mills, Andrew Grigg, J V Melo, Timothy P. Hughes	194
13	Assessing the impacts of tropical cyclones 2008 ·Australian Journal of Emergency Management ·Christopher Arthur, (unknown), (unknown)	9
14	Inflatable rescue boat-related injuries in Queensland surf lifesavers: the epidemiology – biomechanics interface 2005 ·International Journal of Injury Control and Safety Promotion ·(unknown), Christopher Arthur, Timothy M. Barker, David M. Purdie, Rod McClure	4
15	Single dose per cycle pegfilgrastim successfully supports full dose intensity CHOP-14 in patients over 60 years with non-Hodgkin's lymphoma (NHL) and successfully mobilises peripheral blood progenitor cells (PBPC). 2003 ·Blood ·Michael A. Bentley, Paula Marlton, N. Horvath, (unknown), (unknown), Richard Herrmann, Christopher Arthur, Simon Durrant, (unknown), (unknown), (unknown), (unknown)	5
16	Allogeneic haemopoietic cell transplants in Australia, 1996 – A multi-centre retrospective comparison of the use of peripheral blood stem cells with bone marrow 2001 ·Bone Marrow Transplantation ·Ian Nivison‐Smith, KF Bradstock, Jeff Szer, Simon Durrant, Anthony J. Dodds, (unknown), AP Schwarer, John Gibson, LB To, Christopher Arthur, (unknown)	13
17	Comparison ofthallium‐201 and gallium‐67 scintigraphy in soft tissue and bone marrow multiple myeloma: A case report 1997 ·Australasian Radiology ·Paul Roach, Christopher Arthur	4
18	Combined Interferon Alfa-2a and Cytosine Arabinoside as First-Line Treatment for Chronic Myeloid Leukemia 1993 ·Acta Haematologica ·Christopher Arthur, (unknown)	40
19	Effects of taipan (Oxyuranus scutellatus) venom on erythrocyte morphology and blood viscosity in a human victim in vivo and in vitro 1991 ·Transactions of the Royal Society of Tropical Medicine and Hygiene ·Christopher Arthur, Dugald McCallum, (unknown), Anne T. Collins, James P. Isbister, M. McD. Fisher	12
20	Use of minisatellite DNA probes for recognition and characterization of relapse after allogeneic bone marrow transplantation 1988 ·British Journal of Haematology ·(unknown), Jill Hibbin, Christopher Arthur, Jane F. Apperley, Alec J. Jeffreys, John M. Goldman	34

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact